Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for the summary Janey. I'm in Asia and 4.30am less than ideal! Good to hear some big name hospitals in the mix. I'm still a hold here.
Not great but at the end of the day the ticker has gone down a level from otcqb to pink sheets. Ironically pink is where it was when I first bought in. Management says we are still primed for a record revenue year in 2021 so I'm holding. FDA approved products in multiple markets and the outside chance this company gets acquired following a peer that got sold with zero revenue. I'll wait for month end to see if management delivers on financials as they have guided.
I'm still hopeful of a May release of financials. I listened in on the recent presentation and KR did mention it was still in the works. They'd be foolish to mess this up post SOLY news.
FY2020 earnings due out in May I've been informed.
Honestly about the late results I'm not overly concerned. In Hong Kong for example almost a third of the index has filed for late release due to the pandemic. Sanuwave had M&A so its not an unreasonable request. Annual sales guided at 5m vs 1m for 2019. At 5m revenue the company is trading at 17x price to sales at 85m market cap. $SWAV which I consider as a peer is trading at 70x. Also Sanuwave guidance for 2021 is revenue of 25m which at 17x p/s is a 425m market cap which is a share price of $0.9. If I use the SWAV multiple then I get a share price of $3.78. Yes NASDAQ listing is a cherry on the cake but either way it does not take away the growth story which is why we are all here. Good luck
Nada so far. Expect to hear soon though.
Up a penny today and a pound tomorrow ??
My 2c is that the acquisition was primarily for revenues at the target (which was annually $15m). Addl salesforce of course helps for those accounts with no product overlap. On the product front ultramist apparently has synergies with dermapace. In any case the acquisition only just happened so let's see when the numbers are out. Also news on the NASDAQ listing remains pending.
Actually that's a fairy comparison. $SOLY has a market cap of $365m and no revenue? Even though I agree sanuwave revenue numbers look pretty sad right now now, once you add in accretive revenue from the acquisition and their own standalone revenue then market cap should trend higher. Still awaiting date of financials!
Yep I hear you. My hope is that with the institutional investors on board that management will be increasingly focused. I honestly feel that management is trying but as long as revenue is a blip number no one will pay attention. Once we start to see ultramist +dermapace go north of $3-5m a quarter folks will start to pay attention. Especially when NASDAQ listing occurs and there is is more analyst coverage etc etc
If ultramist generated $15m in revenue last year and let's just say sanuwave has zero revenue. This is still trading at only 5.5x sales. Given SWAV (potential peer) is trading at 50x sales what am I missing? Also SWAV annual revenue is about $70m which isn't impossible for sanuwave to achieve/surpass over time.
This below article is certainly not paid media. Encouraging to see the tech is helping ppl. Soon enough investors hopefully see results too ??
https://www.news-herald.com/lifestyle/health/uh-richmond-medical-center-physician-brings-wound-healing-technology-to-ohio/article_0bfda7e4-76de-11eb-99c6-4f90864a4388.html
Popeye the sailor man selling today or what.... Where's the can of spinach? I think sanuwave is in a blackout period pre earnings so no announcements. You are right though, numbers need to be spectacular to instill confidence.
Like Shaggy.. It wasn't me lol. Its encouraging though to see full offer side levels being lifted.
Yes all valid points. The multiple indeed is a show of faith in the ability to execute. Hopefully Q4 data will provide additional confidence once it's out.
Check my math. SWAV is trading at a market cap to LTM revenue of 73x. Let's assume SNWV gets to LTM revenue of $10m (conservative), using the same multiple we get to a market cap of $730m which equates to a share price of approx $1.57. I think annual revenue will be north of $10m, so even if multiple is aggressive we still get to at least $1 per share.
Thanks. So opaleye now holds 6.73% vs how much before?
Actually 3/31 so there's still some time in it.
Also paid research but sexy nonetheless! I must admit the volumes and uptick in price is encouraging. I thought earnings would be out by mid - Feb let's see.
Article out on SANUWAVE:
http://m.digitaljournal.com/pr/4963659
Yes the wait is frustrating but I'm hanging in there. The vote to list is approved, application to NASDAQ sent and hopefully revenue numbers will be supportive. Also institutional investors and banks now involved. BTW is it correct to look at SWAV as a peer? Similar industry, their revenue numbers not too distant from what KR is projecting. From a technical perspective this is lower on dismal volume imo.
Yes 3Q earnings will be key. Also interested to see when NASDAQ listing will take place. Given the tech rally this is an opportune time. Also let's see if the revenue from the recent acquisition gets consolidated into earnings.
Yay Mexico approval. Tequilas all around!
Did I hear right that this company is pursuing a nasdaq listing? Also I don't think this acquisition is clinical phase. Maybe done with the blessing of existing institutional shareholders.